Literature DB >> 9373114

Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis.

D W Park, H Schatz, H R McDonald, R N Johnson.   

Abstract

OBJECTIVE: The purpose of the study is to report the efficacy of laser photocoagulation treatment for macular edema in bilateral juxtafoveal telangiectasis (BJT).
DESIGN: The study design was a retrospective, clinical study. PARTICIPANTS: The authors observed 14 patients with BJT, studying the visual acuities and retinal changes of treated and untreated eyes. MAIN OUTCOME MEASURES: Visual acuity, presence of macular edema, and associated retinal findings were measured.
RESULTS: Of 28 eyes, 10 (8 patients) received 15 laser photocoagulation treatments for macular edema. Neither treated nor untreated eyes had visual improvement of two or more lines. After treatment, five eyes (50%) had increased retinal vascular distortion develop, three (30%) had new draining retinal venules, five (50%) had intraretinal fibrovascular tissues, and four (40%) had retinal and preretinal hemorrhages develop.
CONCLUSIONS: Grid laser photocoagulation therapy for macular edema in patients with BJT appears to neither improve nor stabilize long-term visual acuity. In addition, treatment is associated with retinal pigment epithelial changes, increased postoperative retinal vascular distortion, postoperative vascularized retinal scars, and postoperative retinal hemorrhages. These changes, however, do not appear to cause a further loss of vision.

Entities:  

Mesh:

Year:  1997        PMID: 9373114     DOI: 10.1016/s0161-6420(97)30019-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

1.  Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.

Authors:  Gökhan Demir; Özgür Artunay; Mehmet Emin Sucu; Ali Demircan; Dilek Yaşa; Cengiz Alagöz; Mevlüt Celal Öcal
Journal:  Lasers Med Sci       Date:  2018-05-26       Impact factor: 3.161

2.  Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.

Authors:  Teresa Barth; Florian Zeman; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2017-01-21       Impact factor: 2.031

3.  Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.

Authors:  Yoko Matsumoto; Mitsuko Yuzawa
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

4.  Bevacizumab in the treatment of idiopathic macular telangiectasia.

Authors:  Maria-Andreea Gamulescu; Andreas Walter; Helmut Sachs; Horst Helbig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

5.  Long-term course in type 2 idiopathic macular telangiectasia.

Authors:  Tobias Meyer-ter-Vehn; Sina Herzog; Marc Schargus; Winfried Göbel; Rainer Guthoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-25       Impact factor: 3.117

6.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 7.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

8.  Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study.

Authors:  J Fernando Arevalo; Juan G Sanchez; Reinaldo A Garcia; Lihteh Wu; Maria H Berrocal; Francisco J Rodriguez; Alvaro Rodríguez; Liliana Andrea Novoa; Rafael Garcia-Amaris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-10       Impact factor: 3.117

9.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

10.  Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia.

Authors:  Eric J Sigler; John C Randolph; Jorge I Calzada; Steve Charles
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.